Pfizer Q1FY27 profit up 6.6% as revenue rises 8.3% YoY

Key takeaways from the June quarter

Pfizer Limited reported higher profit and revenue for the quarter ended June 30, 2026 (Q1FY27), with income rising faster than expenses. Net profit increased 6.6% year-on-year to ₹204.47 crore, while revenue from operations rose 8.3% to ₹653.17 crore. The company also reported an expansion in profitability, with EBITDA margin improving to 37.9% from 34.83% in the year-ago quarter. The results were approved by the Board of Directors at its meeting held on July 28, 2026. Separately, Pfizer disclosed the resignation of its Executive Director – Finance and CFO, Amit Agarwal, effective October 8, 2026.

Q1FY27 financial performance: profit, revenue and EPS

For Q1FY27, Pfizer Limited’s net profit rose to ₹204.47 crore from ₹191.75 crore in Q1FY26, a 6.6% increase. Revenue from operations grew to ₹653.17 crore versus ₹603.05 crore in the corresponding quarter last year. Earnings per share (basic and diluted) increased 6.6% to ₹44.69 per share from ₹41.91 per share, and the company noted the quarterly EPS figures were not annualised. Profit before tax (and before exceptional items) rose to ₹276.68 crore from ₹259.53 crore. Pfizer reported no exceptional items in either Q1FY27 or Q1FY26.

Margin expansion and cost trends

The quarter reflected operating leverage as growth in income outpaced the rise in costs. Total expenses increased 2.6% year-on-year to ₹421.33 crore from ₹410.69 crore. Over the same period, EBITDA margin expanded to 37.9% from 34.83%. The company attributed the improvement to better operational leverage and cost management during the quarter. The combination of higher revenue growth and relatively slower expense growth supported the year-on-year improvement in profitability.

Board approval and regulatory compliance

Pfizer’s Board approved the unaudited financial results at a meeting held on July 28, 2026. The statutory auditors, B S R & Co. LLP, issued an unmodified limited review report. The limited review was stated to be in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This is the standard framework that listed companies use for quarterly financial result disclosures.

CFO resignation disclosed

Alongside the quarterly update, Pfizer Limited disclosed that Amit Agarwal, Executive Director – Finance and CFO, resigned effective October 8, 2026. The company said he is pursuing an opportunity outside the company. The disclosure provides clarity on a senior leadership change, which investors typically track given the CFO’s role in capital allocation, financial controls, and market communication.

Quick details shared with the results

The company’s update also carried a “Quick Details” snapshot that included market data and select summary items.

Q1FY27 vs Q1FY26: key numbers at a glance

A year-on-year comparison shows higher operating scale and improved margins.

FY2026 context: income growth, profit decline, and dividend

Earlier, Pfizer Limited announced its audited financial results for the year ended March 31, 2026 (FY2026). It reported net profit of ₹722.43 crore on total income of ₹2,707.60 crore. Total income rose 10.35% year-on-year to ₹2,707.60 crore in FY2026 compared with ₹2,453.60 crore in FY2025, while net profit declined 5.89% to ₹722.43 crore from ₹767.60 crore. The company attributed the profit reduction to rising costs, and it also noted an additional provision of ₹7.43 crore for employee benefits in FY2026, citing developments related to India’s ‘New Labour Codes’.

The Board recommended a final dividend of ₹75 per equity share, subject to shareholder approval at the upcoming Annual General Meeting. The total payout for this dividend was estimated at ₹343.11 crore. Investors were set to await shareholder approval at the AGM scheduled for July 28, 2026, with the payout anticipated on or after August 4, 2026.

Broader market context noted in the update

Ahead of the quarter, an expectation was flagged that Pfizer’s revenue could see double-digit year-on-year growth in Q1, supported by the broader Indian Pharmaceutical Market’s 12% year-on-year growth observed during April to May 2026. The reported Q1FY27 revenue growth came in at 8.3% year-on-year, alongside a sharper improvement in margin.

Global parent context included in the material

The material also referenced Pfizer Inc. (NYSE: PFE) first-quarter 2026 performance and outlook. Pfizer Inc. reported Q1 2026 revenue of $14.451 billion, reported net income attributable to common shareholders of $1.687 billion, reported diluted EPS of $1.47, and adjusted diluted EPS of $1.75. Management reaffirmed full-year 2026 guidance for revenue of $19.5 billion to $12.5 billion and adjusted diluted EPS of $1.80 to $1.00. These figures were presented separately from Pfizer Limited’s India results and are reported in a different currency and reporting framework.

Why the Q1FY27 print matters for investors

For investors tracking Pfizer Limited, the quarter stands out for the combination of mid-single-digit profit growth, higher revenue, and a clear improvement in EBITDA margin. The expense growth of 2.6% against revenue growth of 8.3% helps explain the operational leverage referenced in the company’s commentary. At the same time, the disclosed CFO transition effective October 2026 is a key governance and execution detail that markets generally monitor closely.

Conclusion

Pfizer Limited’s Q1FY27 results showed a year-on-year rise in net profit to ₹204.47 crore and revenue growth to ₹653.17 crore, supported by a higher EBITDA margin of 37.9%. The board approved the unaudited results on July 28, 2026, and the statutory auditors issued an unmodified limited review report. The company also disclosed that its CFO will step down effective October 8, 2026. Shareholders will continue to track the company’s dividend process and subsequent disclosures following the July 28, 2026 meeting and AGM schedule referenced in the update.